Beat Q1 but margin headwinds ahead; guidance unchanged

Delivered ₹422.4 Cr revenue, organic ex-Wokadine 21.4% YoY

Q1 delivered 30.1% YoY (₹60 Cr vs ₹46 Cr), PAT margin 14.2% vs 13.3% prior

Management cites PharmaTrac data; volume growth 5x IPM (6.3% vs 1.3%) evidences outperformance

Q1 margin expansion (EBITDA +190 bps to 22%, PAT +90 bps to 14.2%) consistent with pricing leverage

Management explicitly cautious: 'premature to comment on sustainability' due to geopolitical cost risk; expects ~100 bps hit

Q1 FY26 prior call guided stable margins. This call: 'premature to comment on sustainability'; geopolitical cost risk flagged. EBITDA margin 22% (strong), but warned ~100 bps headwind

Prior guidance: 25% CAGR (₹20 Cr → ₹40 Cr in 3 years). Q1 delivered weak ramp (supply chain phase); management deferred colour to future quarters. Risk to 1.5–2% inorganic guidance

Prior quarter: added 400 MRs (end Q4 FY26). FY27: zero additions. Future: 6–8% annual additions (200–250 MRs). Leverage existing force against 21% growth

EUR-GMP Women's hormone facility commercialized June 30 as planned. Asset turnover <1x in FY27; ramp path established. International dossier filing Nov–Dec 2026

Post-COVID normalization. IPM grew lower single-digit for 20+ years; now sustainable 10% (9–11% range). Expects to stabilize at this level going forward.

97% India business today, aim 90%+ for next 3–5 years. Facility supports both; international ramp expected FY28–29 post-dossier. India-focused thesis unchanged.

Margin driven by product mix, operational leverage. Cautious on extrapolating current levels due to geopolitical volatility. FY27 guidance unchanged (15% revenue, 20% PAT). Operating leverage will support margins over medium term.

Already top-10 in consolidation new business. IPM rank 20th is historical legacy. Cardio growth 15% (IPM benchmark). Portfolio well-placed; focus on maintaining top-10 momentum in new business.

Geopolitical disturbance started Feb 27. Had 70–90 day stock buffer; Q1 less impacted. New stock arriving June onwards. Expect ~100 bps hit; mitigating with cost reduction. Guidance (20% PAT) remains on track.

Internal revenue ₹20 Cr (vs. external ₹28–30 Cr). Targeting ₹20 Cr → ₹40 Cr over 3 years at 25% CAGR. Q1 is integration phase (supply chain). Expect acceleration in coming quarters.

21.4% organic, 21.9% total. 85% of ₹100 Cr growth came organic; 15% inorganic (old acquisitions 3–4 years back). Wokadine is first-year inorganic (measured separately for 25% target).

Added 400 MRs end Q4 FY26. FY27 leverage those; future target 6–8% annual additions (200–250/year). Guidance (15% revenue, 20% PAT) achievable with this plan.

Facility started June 30 (quarter-end). Asset turnover <1x in FY27, rises to 2–3x over 3 years. No material opex impact yet (costs capitalized pre-commissioning).

GLP-1 market opportunity (₹1,500–1,800 Cr). Aiming top-10 position; focus is on core engine brands vs. semaglutide. Getting good results from engine brand strategy.

All organic. Both organically developed and scaled. Shows strength of brand-building machine.

31% stake (associate company). Supplies progesterone, dydrogesterone, norethisterone, etc. ~60–65% of hormonal API sourced from La Chandra; balance from other global suppliers.

Q1 delivered 21.4% organic vs 15% target. Management explicitly cautious on annualizing; cites IPM expected to stabilize 9–11%, expects outperformance maintained but not guaranted. Inorganic headwind: Wokadine underperforming in Q1 (supply chain phase); 25% CAGR target under risk.

Explicitly cautious: 'premature to comment on sustainability of current levels.' Geopolitical raw material cost headwind ~100 bps expected in Q2+. Favorable product mix and operating leverage cited as offsets, but no numbers guaranted.

Facility operational June 30. Depreciation ~₹6.5 Cr/year (20-year amortization). FY27–28 ramp-up phase; international dossier filing targeted Nov–Dec 2026, exports FY28–29

Geopolitical disturbance began Feb 27, 2026. Management had 70–90 day inventory buffer; Q1 less impacted. New procurement arriving June onwards. Expects ~100 bps PAT headwind in Q2+. Volatility duration and magnitude difficult to predict.

Wokadine acquired Dec 2025 for ₹97 Cr; guided 25% CAGR (₹20 Cr internal revenue → ₹40 Cr in 3 years). Q1 showed weak ramp; management attributed to supply-chain integration phase. Risk: CAGR target becomes unachievable if ramp remains sluggish in Q2–Q3.

₹130 Cr capex facility commercialized June 30. Management projects turnover ratio <1x in FY27, rising to 2–3x over 3 years. Risk: if ramp slower than expected, ROIC poor in FY27–28; depreciation drag (~₹6.5 Cr/year) limits PAT accretion until utilization improves.

International revenue 3% of total. Long-term target: higher single-digit after 5 years. Hormone facility EU-GMP dossier submission Nov–Dec 2026; regulatory approval estimated 12–18 months (FY28–29 kick-off). Risk: regulatory delays or rejection derail export growth; facility utilization remains domestic-dependent longer.

Q1 showed EBITDA margin +190 bps (22%) and PAT margin +90 bps (14.2%) on favorable chronic mix and leverage. Management explicitly cautious: 'premature to comment on sustainability... given evolving cost environment.' If geopolitical inflation persists and pricing power exhausted, margins compress.